Details

Autor(en) / Beteiligte

• Shi, Dai
• Xie, Siwei
• Li, Anqi
• Wang, Qingyong
• Guo, Hongbo
• Han, Ying
• Xu, Huaxi
• Gan, Wen-Biao
• Zhang, Lei
• Guo, Tengfei

Titel

APOE-ε4 modulates the association among plasma Aβ42/Aβ40, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults

Ist Teil von

• Translational psychiatry, 2022-03, Vol.12 (1), p.128-128, Article 128

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Abstract Including apolipoprotein E-ε4 (APOE-ε4) status and older age into consideration may increase the accuracy of plasma Aβ 42 /Aβ 40 detecting Aβ+ individuals, but the rationale behind this remains to be fully understood. Besides, both Aβ pathology and vascular diseases are related to neurodegeneration and cognitive decline, but it is still not fully understood how APOE-ε4 modulates these relationships. In this study, we examined 241 non-demented Alzheimer’s Disease Neuroimaging Initiative participants to investigate the associations among age, white matter hyperintensities (WMH), hypertension, hyperlipidemia, body mass index (BMI), plasma Aβ 42 /Aβ 40 measured by liquid chromatography tandem mass spectrometry, and 18 F-florbetapir Aβ PET as well as their prediction of longitudinal adjusted hippocampal volume (aHCV) and cognition in APOE-ε4 carriers and non-carriers. We found older age predicted faster WMH increase ( p  = 0.024) and cortical Aβ accumulation ( p  = 0.043) in APOE-ε4 non-carriers only, whereas lower plasma Aβ 42 /Aβ 40 predicted faster cortical Aβ accumulation ( p  < 0.018) regardless of APOE-ε4 status. While larger WMH and underweight predicted ( p  < 0.05) faster decreases in aHCV and cognition in APOE-ε4 non-carriers, lower plasma Aβ 42 /Aβ 40 predicted ( p  < 0.031) faster decreases in aHCV and cognition in APOE-ε4 carriers. Higher Aβ PET also predicted faster rates of aHCV ( p  = 0.010) in APOE-ε4 carriers only, but was related to faster rates of cognitive decline ( p  < 0.022) regardless of APOE-ε4 status. These findings may provide novel insights into understanding different mechanisms underlie neurodegeneration and cognitive decline in non-demented elderly adults with and without APOE-ε4 allele, which may help the design of anti-Alzheimer’s clinical trials.